Solriamfetol 300 mg

DRUG4 trials

Sponsors

Axsome Therapeutics, Inc.

Conditions

ADHDBinge-Eating DisorderExcessive SleepinessMajor Depressive DisorderShift-work Disorder

Phase 3

A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

CompletedNCT05972044

Axsome Therapeutics, Inc.ADHD

Start: 2023-07-06End: 2025-03-14Updated: 2026-02-10

Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol

CompletedNCT06360419

Axsome Therapeutics, Inc.Major Depressive Disorder

Start: 2024-03-18End: 2025-03-26Updated: 2026-01-05

Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

RecruitingNCT06413433

Axsome Therapeutics, Inc.Binge-Eating Disorder

Start: 2024-04-26End: 2026-12-01Target: 450Updated: 2026-07-28

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

RecruitingNCT06568367

Axsome Therapeutics, Inc.Excessive Sleepiness, Shift-work Disorder

Start: 2024-08-01End: 2026-12-01Target: 520Updated: 2026-07-24